GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (WBO:VRTX) » Definitions » Shiller PE Ratio

Vertex Pharmaceuticals (WBO:VRTX) Shiller PE Ratio : 70.13 (As of May. 02, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Vertex Pharmaceuticals Shiller PE Ratio?

As of today (2024-05-02), Vertex Pharmaceuticals's current share price is €375.20. Vertex Pharmaceuticals's E10 for the quarter that ended in Dec. 2023 was €5.35. Vertex Pharmaceuticals's Shiller PE Ratio for today is 70.13.

The historical rank and industry rank for Vertex Pharmaceuticals's Shiller PE Ratio or its related term are showing as below:

WBO:VRTX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 63.32   Med: 90.4   Max: 8209.67
Current: 68.66

During the past years, Vertex Pharmaceuticals's highest Shiller PE Ratio was 8209.67. The lowest was 63.32. And the median was 90.40.

WBO:VRTX's Shiller PE Ratio is ranked worse than
76.67% of 150 companies
in the Biotechnology industry
Industry Median: 35.23 vs WBO:VRTX: 68.66

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Vertex Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was €3.402. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is €5.35 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Vertex Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Vertex Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vertex Pharmaceuticals Shiller PE Ratio Chart

Vertex Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7,147.96 155.85 86.51 71.14 69.46

Vertex Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 71.14 68.75 70.12 62.87 69.46

Competitive Comparison of Vertex Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Vertex Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vertex Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Vertex Pharmaceuticals's Shiller PE Ratio falls into.



Vertex Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Vertex Pharmaceuticals's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=375.20/5.35
=70.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vertex Pharmaceuticals's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Vertex Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=3.402/129.4194*129.4194
=3.402

Current CPI (Dec. 2023) = 129.4194.

Vertex Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.723 99.695 -0.939
201406 -0.500 100.560 -0.643
201409 -0.559 100.428 -0.720
201412 -0.600 99.070 -0.784
201503 -0.767 99.621 -0.996
201506 -0.695 100.684 -0.893
201509 -0.347 100.392 -0.447
201512 -0.285 99.792 -0.370
201603 -0.153 100.470 -0.197
201606 -0.231 101.688 -0.294
201609 -0.143 101.861 -0.182
201612 0.123 101.863 0.156
201703 0.926 102.862 1.165
201706 0.062 103.349 0.078
201709 -0.344 104.136 -0.428
201712 0.330 104.011 0.411
201803 0.657 105.290 0.808
201806 0.685 106.317 0.834
201809 0.429 106.507 0.521
201812 5.248 105.998 6.408
201903 0.912 107.251 1.101
201906 0.912 108.070 1.092
201909 0.200 108.329 0.239
201912 2.007 108.420 2.396
202003 2.072 108.902 2.462
202006 2.824 108.767 3.360
202009 2.148 109.815 2.531
202012 1.891 109.897 2.227
202103 2.092 111.754 2.423
202106 0.216 114.631 0.244
202109 2.788 115.734 3.118
202112 2.655 117.630 2.921
202203 2.688 121.301 2.868
202206 2.961 125.017 3.065
202209 3.626 125.227 3.747
202212 2.974 125.222 3.074
202303 2.512 127.348 2.553
202306 3.249 128.729 3.266
202309 3.720 129.860 3.707
202312 3.402 129.419 3.402

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Vertex Pharmaceuticals  (WBO:VRTX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Vertex Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Vertex Pharmaceuticals (WBO:VRTX) Business Description

Address
50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.